SER150

SER150
Clinical data
Other names	EV 077; ICI 192605 (racemic)
Identifiers
	IUPAC name (4Z)-6-[(2R,4R,5S)-2-(2-Chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl]-4-hexenoic acid;
CAS Number	1041850-31-0 ; 117621-64-4 (racemic);
PubChem CID	6604763;
Chemical and physical data
Formula	C22H23ClO5
Molar mass	402.87 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C(/C=C\CCC(O)=O)[C@H]1[C@H](O[C@H](OC1)C2=C(Cl)C=CC=C2)C3=C(O)C=CC=C3;
	InChI InChI=1S/C22H23ClO5/c23-18-11-6-4-9-16(18)22-27-14-15(8-2-1-3-13-20(25)26)21(28-22)17-10-5-7-12-19(17)24/h1-2,4-7,9-12,15,21-22,24H,3,8,13-14H2,(H,25,26)/b2-1-/t15-,21+,22+/m1/s1; Key:WHUIENZXNGAHQI-GKZDNZBASA-N;

SER150 (formerly EV 077) is an inhibitor of thromboxane synthase and an antagonist of the thromboxane prostanoid receptor. It was developed for diabetic nephropathy.^[1]^[2]^[3]

References

^ Kim, Yoon Kook; Ning, Xinyuan; Munir, Kashif M.; Davis, Stephen N. (2 October 2022). "Emerging drugs for the treatment of diabetic nephropathy". Expert Opinion on Emerging Drugs. 27 (4): 417–430. doi:10.1080/14728214.2022.2155632.
^ McFarlane, Samy I. (2020). Kidney Disease in Diabetes. Bentham Science Publishers. p. 101. ISBN 978-981-14-2199-0.
^ Tan, Seng Kiong; Cooper, Mark E. (28 October 2023). "Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?". Expert Opinion on Emerging Drugs. 28 (4): 217–226. doi:10.1080/14728214.2023.2277762.